Corsair Pharma Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Private

  • Employees
  • 5

Employees

  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $23M

  • Investors
  • 6

Corsair Pharma General Information

Description

Developer of novel treprostinil drugs designed to improve the therapeutic profile of medications and provide superior treatment options for patients. The company focuses on delivering an inactive prodrug of treprostinil, which is designed to cross the skin, enter the blood, and convert rapidly to treprostinil in the liver, that has the potential to offer efficacy and fast titration of parenteral delivery, enabling healthcare professionals to treat patients using a once-daily transdermal patch.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 5600 Mowry School Road
  • Suite 330
  • Newark, CA 94560
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 5600 Mowry School Road
  • Suite 330
  • Newark, CA 94560
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Corsair Pharma Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Later Stage VC (Series B) 20-Sep-2023 $23M Completed Clinical Trials - Phase 1
1. Secondary Transaction - Private 04-Jan-2018 Completed Clinical Trials - Phase 1
To view Corsair Pharma’s complete valuation and funding history, request access »

Corsair Pharma Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of novel treprostinil drugs designed to improve the therapeutic profile of medications and provide superior tr
Drug Discovery
Newark, CA
5 As of 2023

Norcross, GA
 

Saint Louis, MO
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Corsair Pharma Competitors (4)

One of Corsair Pharma’s 4 competitors is Galectin Therapeutics, a Corporation company based in Norcross, GA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Galectin Therapeutics Corporation Norcross, GA
APT Therapeutics Venture Capital-Backed Saint Louis, MO
Gossamer Bio Formerly VC-backed San Diego, CA
Peloton Therapeutics Formerly VC-backed Dallas, TX
To view Corsair Pharma’s complete competitors history, request access »

Corsair Pharma Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Corsair Pharma Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds
Junson Capital Asset Manager Minority
Midas Capital Partners Corporation Minority
New Rhein Healthcare Venture Capital Minority
Plaisance Capital Management Venture Capital Minority
Primavera Capital Group Growth/Expansion Minority
You’re viewing 5 of 6 investors. Get the full list »

Corsair Pharma FAQs

  • When was Corsair Pharma founded?

    Corsair Pharma was founded in 2014.

  • Where is Corsair Pharma headquartered?

    Corsair Pharma is headquartered in Newark, CA.

  • What is the size of Corsair Pharma?

    Corsair Pharma has 5 total employees.

  • What industry is Corsair Pharma in?

    Corsair Pharma’s primary industry is Drug Discovery.

  • Is Corsair Pharma a private or public company?

    Corsair Pharma is a Private company.

  • What is Corsair Pharma’s current revenue?

    The current revenue for Corsair Pharma is .

  • How much funding has Corsair Pharma raised over time?

    Corsair Pharma has raised $23M.

  • Who are Corsair Pharma’s investors?

    Junson Capital, Midas Capital Partners, New Rhein Healthcare, Plaisance Capital Management, and Primavera Capital Group are 5 of 6 investors who have invested in Corsair Pharma.

  • Who are Corsair Pharma’s competitors?

    Galectin Therapeutics, APT Therapeutics, Gossamer Bio, and Peloton Therapeutics are competitors of Corsair Pharma.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process